Hypertension is an insidious and silent disease that is diagnosed relatively
late due to its asymptomatic course. It is considered one of the most substantial major
risk factor for fatal cardiovascular diseases in entire world especially people who live
in developed communities. Epidemiological statistics and public health concerns are
resulting in a need for an objective biomarker for this remedy. This necessity is quite
crucial for hypertension due to available treatment options, silent clinical outcome
progressing and discrepancy between blood pressure measurement methods. The use of
biomarkers can contribute not only to pre-diagnosis but also to disease follow-up,
treatment success, and prognosis estimation and complication analysis as a whole. As a
general concept, biological markers can be located at various sites like systemic
circulation, urine, pleural fluid, pericardial fluid, peritoneal cavity, synovial fluid,
aqueous humor and even cerebrospinal fluid. Researchers are steadily trying to develop
new markers to medical usage or pre-existing ones are being modified for new or
enlarged purposes. Analysis methods are also becoming more accessible with less
intense labor and less expensive thanks to high technology. Regardless of the tissue
from which the biomarker is taken and difficulty in measurement procedures, it will
always be a serious target to contribute new, more sensitive and more specific
biomarkers on hypertension in clinical biochemistry.
Keywords: Aldosterone, Analysis, Biomarker, Cardiovascular, Decision
threshold, Differential diagnosis, Essential hypertension, Fibrinogen, Laboratory,
Metanephrine, Microalbumin, Normetanephrine, Oxidized LDL, Prehypertension,
Prognosis, Prostocycline, Renin, Screening, Silent clinic,
Sphygmomanometer.
